Oragenics Granted Approval to Commence Phase II Trial for Neuroprotective Therapy
Oragenics receives approval to start Phase II trial for neuroprotective therapy for mild traumatic brain injury, showcasing progress in potential treatment development.
This news matters because it signifies a significant step in the development of a potential treatment for mild traumatic brain injury. The approval for the clinical trial opens doors for Oragenics to expand its program internationally, potentially benefiting patients suffering from concussions globally.
